Abediterol

Abediterol
Clinical data
Routes of; administration	Inhalation
ATC code	None;
Pharmacokinetic data
Elimination half-life	24.3 hours
Identifiers
	IUPAC name 5-[(1R)-2-{[6-(2,2-Difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl]-8-hydroxyquinolin-2(1H)-one;
CAS Number	915133-65-2;
PubChem CID	11962616;
ChemSpider	10136846 ;
UNII	QXA167CM6F;
KEGG	D10219 ;
ChEBI	CHEBI:142077;
ChEMBL	ChEMBL3039530 ;
CompTox Dashboard (EPA)	DTXSID60238605 ;
Chemical and physical data
Formula	C25H30F2N2O4
Molar mass	460.522 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES FC(F)(c1ccccc1)COCCCCCCNC[C@H](O)c3ccc(O)c2c3\C=C/C(=O)N2;
	InChI InChI=1S/C25H30F2N2O4/c26-25(27,18-8-4-3-5-9-18)17-33-15-7-2-1-6-14-28-16-22(31)19-10-12-21(30)24-20(19)11-13-23(32)29-24/h3-5,8-13,22,28,30-31H,1-2,6-7,14-17H2,(H,29,32)/t22-/m0/s1 ; Key:SFYAXIFVXBKRPK-QFIPXVFZSA-N ;

Abediterol (INN;^[2] development codes AZD-0548 and LAS 100977) is a once-daily experimental drug candidate for the treatment of asthma and chronic obstructive pulmonary disease (COPD). It is currently under development by the Spanish pharmaceutical company Almirall and is in Phase II clinical trials.^[3]^[4]

It acts as a dual β₂ adrenergic agonist^[5]^[6] and muscarinic antagonist and is classified as an ultra-long-acting β₂ agonist (ultra-LABA).^[7]

Its coformulation with mometasone furoate is also in Phase II clinical trials.^[8]^[when?]^{[needs update]}

References[]

^ Timmer W, Massana E, Jimenez E, Seoane B, de Miquel G, Ruiz S (December 2014). "First-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of abediterol (LAS100977), a novel long-acting Β2 -agonist". Journal of Clinical Pharmacology. 54 (12): 1347–53. doi:10.1002/jcph.355. PMID 24989946. S2CID 20959248.
^ "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed International Nonproprietary Names: List 104" (PDF). WHO Drug Information. 24 (1): 352. 2010. Retrieved 25 March 2016.
^ Product development pipeline, Almirall
^ "AdisInsight: Abediterol". Adis Insight. Springer International Publishing AG. Retrieved 25 March 2016.
^ "Espacenet - Bibliographic data". worldwide.espacenet.com. Retrieved 2021-05-07.
^ "Espacenet - Bibliographic data". worldwide.espacenet.com. Retrieved 2021-05-07.
^ Beier J, Fuhr R, Massana E, Jiménez E, Seoane B, de Miquel G, Ruiz S (October 2014). "Abediterol (LAS100977), a novel long-acting β2-agonist: efficacy, safety and tolerability in persistent asthma". Respiratory Medicine. 108 (10): 1424–9. doi:10.1016/j.rmed.2014.08.005. PMID 25256258.
^ "AdisInsight: Abediterol/mometasone". Adis Insight. Springer International Publishing AG. Retrieved 25 March 2016.

This drug article relating to the respiratory system is a stub. You can help Wikipedia by .

[1] Timmer W, Massana E, Jimenez E, Seoane B, de Miquel G, Ruiz S (December 2014). "First-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of abediterol (LAS100977), a novel long-acting Β2 -agonist". Journal of Clinical Pharmacology. 54 (12): 1347–53. doi:10.1002/jcph.355. PMID 24989946. S2CID 20959248.

[2] "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed International Nonproprietary Names: List 104" (PDF). WHO Drug Information. 24 (1): 352. 2010. Retrieved 25 March 2016.

[3] Product development pipeline, Almirall

[4] "AdisInsight: Abediterol". Adis Insight. Springer International Publishing AG. Retrieved 25 March 2016.

[5] "Espacenet - Bibliographic data". worldwide.espacenet.com. Retrieved 2021-05-07.

[6] "Espacenet - Bibliographic data". worldwide.espacenet.com. Retrieved 2021-05-07.

[7] Beier J, Fuhr R, Massana E, Jiménez E, Seoane B, de Miquel G, Ruiz S (October 2014). "Abediterol (LAS100977), a novel long-acting β2-agonist: efficacy, safety and tolerability in persistent asthma". Respiratory Medicine. 108 (10): 1424–9. doi:10.1016/j.rmed.2014.08.005. PMID 25256258.

[8] "AdisInsight: Abediterol/mometasone". Adis Insight. Springer International Publishing AG. Retrieved 25 March 2016.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

Clinical data

Routes of administration	Inhalation
ATC code	None
Pharmacokinetic data
Elimination half-life	24.3 hours^[1]
Identifiers
IUPAC name 5-[(1R)-2-{[6-(2,2-Difluoro-2-phenylethoxy)hexyl]amino}-1-hydroxyethyl]-8-hydroxyquinolin-2(1H)-one
CAS Number	915133-65-2
PubChem CID	11962616
ChemSpider	10136846^Y
UNII	QXA167CM6F
KEGG	D10219^Y
ChEBI	CHEBI:142077
ChEMBL	ChEMBL3039530^Y
CompTox Dashboard (EPA)	DTXSID60238605
Chemical and physical data
Formula	C₂₅H₃₀F₂N₂O₄
Molar mass	460.522 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES FC(F)(c1ccccc1)COCCCCCCNC[C@H](O)c3ccc(O)c2c3\C=C/C(=O)N2
InChI InChI=1S/C25H30F2N2O4/c26-25(27,18-8-4-3-5-9-18)17-33-15-7-2-1-6-14-28-16-22(31)19-10-12-21(30)24-20(19)11-13-23(32)29-24/h3-5,8-13,22,28,30-31H,1-2,6-7,14-17H2,(H,29,32)/t22-/m0/s1^Y Key:SFYAXIFVXBKRPK-QFIPXVFZSA-N^Y